Guo S, Counte MA, Gillespie KN, Schmitz H, et al.
International journal of technology assessment in health care. Date of publication 2003 Oct 1;volume 19(4):731-7.
1. Int J Technol Assess Health Care. 2003 Fall;19(4):731-7.
Cost-effectiveness of adjunctive hyperbaric oxygen in the treatment of diabetic
ulcers.
Guo S(1), Counte MA, Gillespie KN, Schmitz H.
Author information:
(1)Department of Health Management and Policy, School of Public Health, Saint
Louis University, MO 63104, USA.
OBJECTIVES: This study estimates the cost-effectiveness (CE) of the adjunctive
use of hyperbaric oxygen (HBO2) therapy in the treatment of diabetic ulcers based
on the payer's and societal perspectives.
METHODS: The study population was a hypothetical cohort of 1,000 patients sixty
years of age with severe diabetic foot ulcers. A decision tree model was
constructed to estimate the CE of HBO2 therapy in the treatment of diabetic
ulcers at years 1, 5, and 12. Scenario and one-way sensitivity analyses were also
undertaken to identify parameters that may significantly influence the estimates.
RESULTS: The CE model estimated that the incremental cost per additional
quality-adjusted life year (QALY) gained at years 1, 5, and 12, was dollar
27,310, dollar 5,166, and dollar 2,255, respectively.
CONCLUSIONS: The study results indicate that HBO2 therapy in the treatment of
diabetic ulcers is cost-effective, particularly based on a long-term perspective.
However, the results are limited by the clinical studies that provide the basis
of the CE estimation.
PMID: 15095781 [Indexed for MEDLINE]
